IIVS | Assays Inflammatory Cytokine Expression
archive,tax-assay,term-inflammatory-cytokine-expression,term-82,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-,vc_responsive


Webinar: How GLPs Enhance the Quality of Regulated and Non-Regulated Toxicology

October 18, 2016
This one-hour webinar, led by IIVS Director of Quality and Compliance, introduces some of the concepts of Good Laboratory Practices (GLPs) designed to promote study and data integrity within an in vitro toxicology framework. Applying these concepts within your own laboratory should aid in production of robust, repeatable studies. View Slides...

Inflammatory Cytokine Expression

August 24, 2016
Product Safety Assessment Using an In Vitro Test System Based on Viability of and Cytokine Released by Reconstructed Human Epidermis (RhE) Models Assay used for the evaluation of the skin irritation potential of topically administered test materials Frequently used to address the irritation profile of (but not limited to) surfactant-based formulations with rinse-off applications The assay allows ranking of test materials with anticipated low irritation potential using pro-inflammatory cytokine analyses such as interleukin IL-1α Assay Endpoints Tissue viability Cytokine expression Applicability Domain ...

Next Generation Tobacco Products

August 24, 2016
IIVS has a long-standing history of working with various industries to help establish or utilize in vitro models for the prediction of risk and the assessment of products under development. With the Food and Drug Administration extending its authority to all tobacco products (including e-cigarettes, cigars, and hookah) the tobacco industry is faced with the task of assessing product safety for product development and regulatory submission. Further, the manufacture of tobacco products may entail risk to workers that come in...